Overview

Epoprostenol for Injection in Patients With Pulmonary Arterial Hypertension

Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
This is an open-label, nonrandomized extension to study AC-066A301. The study will assess safety and tolerability of ACT-385781A while providing a means for continuing treatment after ending participation in study AC-066A301.
Phase:
Phase 3
Details
Lead Sponsor:
Actelion
Collaborators:
Chiltern International Ltd.
Effi-Stat
Treatments:
Epoprostenol
Tezosentan